Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.
Birgit S GeurtsLaurien J ZeverijnLindsay V M LeekJ Maxime van Berge HenegouwenLouisa R HoesHanneke van der WijngaartVincent van den NoortJoris van de HaarAnnemiek van Ommen-NijhofMarleen KokPaul RoepmanAnne M L JansenWendy W J de LengMaja J A de JongeAnn HoebenCarla M L van HerpenHans M WestgeestLodewyk F A WesselsHenk M W VerheulAndré B P van KuilenburgEmile E VoestPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Although pembrolizumab lacked activity in cohort A, cohorts B and C met the study's primary endpoint. Further research is warranted to refine the selection of patients with tumors harboring lower TMLs and may benefit from a focus on innate immunity. See related commentary by Hsu and Yen, p. 3652.